Hearings and Votes Archive
To view hearings and votes that took place prior to January 2012, please visit the legacy version of the Energy and Commerce Committee website here.
Reauthorization of PDUFA: What It Means for Jobs, Innovation, and Patients
Wednesday, February 1, 2012 - 10:00am
2123 Rayburn
Background Documents and Information:
Opening Statements:
Witnesses:
Panel I
The Honorable Margaret A. Hamburg, M.D.
- Commissioner
- U.S. Food and Drug Administration
- Witness Testimony (Truth in Testimony)
Panel II
Mr. Geno Germano
- President and General Manager
- Specialty Care and Oncology
- Pfizer, Inc.
- Witness Testimony (Truth in Testimony)
Dr. David L. Gollaher
- President and CEO
- CHI-California Healthcare Institute
- Witness Testimony (Truth in Testimony)
Mr. Richard F. Pops
- Chairman and CEO
- Alkermes
- On behalf of
- Biotechnology Industry Organization
- Witness Testimony (Truth in Testimony)
Mr. Allan Coukell
- Director, Medical Programs
- Pew Health Group
- The Pew Charitable Trusts
- Witness Testimony (Truth in Testimony)
Ms. Diane Edquist Dorman
- Vice President
- Public Policy
- National Organization of Rare Disorders
- Witness Testimony (Truth in Testimony)
Dr. David E. Wheadon
- Senior Vice President
- Scientific and Regulatory Affairs
- Pharmaceutical Research and Manufacturers of America
- Witness Testimony (Truth in Testimony)
Dr. Daniel A.C. Frattarelli
- Chair, American Academy of Pediatrics’ Committee on Drugs
- Oakwood Hospital and Medical Center and Medical Center
- On behalf of
- American Academy of Pediatrics' Committee on Drugs
- Witness Testimony (Truth in Testimony)
Congress: